The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey

We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic...

Full description

Saved in:
Bibliographic Details
Main Authors: Bocchetta, Martina (Author) , Frölich, Lutz (Author)
Format: Article (Journal)
Language:English
Published: February 2015
In: Alzheimer's and dementia
Year: 2015, Volume: 11, Issue: 2, Pages: 195-206.e1
ISSN:1552-5279
DOI:10.1016/j.jalz.2014.06.006
Online Access:Verlag, Volltext: http://dx.doi.org/10.1016/j.jalz.2014.06.006
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1552526014024650
Get full text
Author Notes:Martina Bocchetta, Samantha Galluzzi, Patrick Gavin Kehoe, Eduardo Aguera, Roberto Bernabei, Roger Bullock, Mathieu Ceccaldi, Jean-François Dartigues, Alexandre de Mendonça, Mira Didic, Maria Eriksdotter, Olivier Félician, Lutz Frölich, Hermann-Josef Gertz, Merja Hallikainen, Steen G. Hasselbalch, Lucrezia Hausner, Isabell Heuser, Frank Jessen, Roy W. Jones, Alexander Kurz, Brian Lawlor, Alberto Lleo, Pablo Martinez-Lage, Patrizia Mecocci, Shima Mehrabian, Andreas Monsch, Flavio Nobili, Agneta Nordberg, Marcel Olde Rikkert, Jean-Marc Orgogozo, Florence Pasquier, Oliver Peters, Eric Salmon, Carmen Sánchez-Castellano, Isabel Santana, Marie Sarazin, Latchezar Traykov, Magda Tsolaki, Pieter Jelle Visser, Åsa K. Wallin, Gordon Wilcock, David Wilkinson, Henrike Wolf, Görsev Yener, Dina Zekry, Giovanni B. Frisoni

MARC

LEADER 00000caa a2200000 c 4500
001 1562916866
003 DE-627
005 20240316100225.0
007 cr uuu---uuuuu
008 170830s2015 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.jalz.2014.06.006  |2 doi 
035 |a (DE-627)1562916866 
035 |a (DE-576)492916861 
035 |a (DE-599)BSZ492916861 
035 |a (OCoLC)1340978921 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Bocchetta, Martina  |d 1986-  |e VerfasserIn  |0 (DE-588)1139073397  |0 (DE-627)896676013  |0 (DE-576)492916152  |4 aut 
245 1 4 |a The use of biomarkers for the etiologic diagnosis of MCI in Europe  |b an EADC survey  |c Martina Bocchetta, Samantha Galluzzi, Patrick Gavin Kehoe, Eduardo Aguera, Roberto Bernabei, Roger Bullock, Mathieu Ceccaldi, Jean-François Dartigues, Alexandre de Mendonça, Mira Didic, Maria Eriksdotter, Olivier Félician, Lutz Frölich, Hermann-Josef Gertz, Merja Hallikainen, Steen G. Hasselbalch, Lucrezia Hausner, Isabell Heuser, Frank Jessen, Roy W. Jones, Alexander Kurz, Brian Lawlor, Alberto Lleo, Pablo Martinez-Lage, Patrizia Mecocci, Shima Mehrabian, Andreas Monsch, Flavio Nobili, Agneta Nordberg, Marcel Olde Rikkert, Jean-Marc Orgogozo, Florence Pasquier, Oliver Peters, Eric Salmon, Carmen Sánchez-Castellano, Isabel Santana, Marie Sarazin, Latchezar Traykov, Magda Tsolaki, Pieter Jelle Visser, Åsa K. Wallin, Gordon Wilcock, David Wilkinson, Henrike Wolf, Görsev Yener, Dina Zekry, Giovanni B. Frisoni 
264 1 |c February 2015 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 30.08.2017 
520 |a We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Aβ42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it “always/frequently”) followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as “moderate”. Seventy-nine percent of responders felt “very/extremely” comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature. 
650 4 |a Alzheimer's disease 
650 4 |a Biomarkers 
650 4 |a Diagnosis 
650 4 |a Mild cognitive impairment 
700 1 |a Frölich, Lutz  |d 1956-  |e VerfasserIn  |0 (DE-588)1028327099  |0 (DE-627)730567516  |0 (DE-576)375813160  |4 aut 
773 0 8 |i Enthalten in  |t Alzheimer's and dementia  |d Hoboken, NJ : Wiley, 2005  |g 11(2015), 2, Seite 195-206.e1  |h Online-Ressource  |w (DE-627)499546059  |w (DE-600)2201940-6  |w (DE-576)255666330  |x 1552-5279  |7 nnas  |a The use of biomarkers for the etiologic diagnosis of MCI in Europe an EADC survey 
773 1 8 |g volume:11  |g year:2015  |g number:2  |g pages:195-206.e1  |g extent:13  |a The use of biomarkers for the etiologic diagnosis of MCI in Europe an EADC survey 
856 4 0 |u http://dx.doi.org/10.1016/j.jalz.2014.06.006  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S1552526014024650  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20170830 
993 |a Article 
994 |a 2015 
998 |g 1028327099  |a Frölich, Lutz  |m 1028327099:Frölich, Lutz  |d 60000  |e 60000PF1028327099  |k 0/60000/  |p 13 
999 |a KXP-PPN1562916866  |e 2978903430 
BIB |a Y 
SER |a journal 
JSO |a {"id":{"eki":["1562916866"],"doi":["10.1016/j.jalz.2014.06.006"]},"name":{"displayForm":["Martina Bocchetta, Samantha Galluzzi, Patrick Gavin Kehoe, Eduardo Aguera, Roberto Bernabei, Roger Bullock, Mathieu Ceccaldi, Jean-François Dartigues, Alexandre de Mendonça, Mira Didic, Maria Eriksdotter, Olivier Félician, Lutz Frölich, Hermann-Josef Gertz, Merja Hallikainen, Steen G. Hasselbalch, Lucrezia Hausner, Isabell Heuser, Frank Jessen, Roy W. Jones, Alexander Kurz, Brian Lawlor, Alberto Lleo, Pablo Martinez-Lage, Patrizia Mecocci, Shima Mehrabian, Andreas Monsch, Flavio Nobili, Agneta Nordberg, Marcel Olde Rikkert, Jean-Marc Orgogozo, Florence Pasquier, Oliver Peters, Eric Salmon, Carmen Sánchez-Castellano, Isabel Santana, Marie Sarazin, Latchezar Traykov, Magda Tsolaki, Pieter Jelle Visser, Åsa K. Wallin, Gordon Wilcock, David Wilkinson, Henrike Wolf, Görsev Yener, Dina Zekry, Giovanni B. Frisoni"]},"physDesc":[{"extent":"13 S."}],"relHost":[{"language":["eng"],"part":{"text":"11(2015), 2, Seite 195-206.e1","issue":"2","pages":"195-206.e1","year":"2015","volume":"11","extent":"13"},"origin":[{"publisherPlace":"Hoboken, NJ ; Amsterdam","dateIssuedDisp":"2005-","dateIssuedKey":"2005","publisher":"Wiley ; Elsevier"}],"note":["Gesehen am 19.03.2024"],"pubHistory":["1.2005 -"],"title":[{"title":"Alzheimer's and dementia","subtitle":"the journal of the Alzheimer's Association","title_sort":"Alzheimer's and dementia"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"The use of biomarkers for the etiologic diagnosis of MCI in Europe an EADC surveyAlzheimer's and dementia","physDesc":[{"extent":"Online-Ressource"}],"recId":"499546059","id":{"eki":["499546059"],"doi":["10.1002/(ISSN)1552-5279"],"issn":["1552-5279"],"zdb":["2201940-6"]}}],"recId":"1562916866","type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 30.08.2017"],"origin":[{"dateIssuedDisp":"February 2015","dateIssuedKey":"2015"}],"title":[{"title":"The use of biomarkers for the etiologic diagnosis of MCI in Europe","title_sort":"use of biomarkers for the etiologic diagnosis of MCI in Europe","subtitle":"an EADC survey"}],"language":["eng"],"person":[{"family":"Bocchetta","display":"Bocchetta, Martina","given":"Martina","role":"aut"},{"role":"aut","given":"Lutz","display":"Frölich, Lutz","family":"Frölich"}]} 
SRT |a BOCCHETTAMUSEOFBIOMA2015